Effect of angiotensin II receptor blocker therapy on markers of fibrosis and immune inflammation in hypertensive patients with chronic kidney disease after ischemic stroke
Aim. To compare the effect of angiotensin II receptor blocker therapy (azilsartan, telmisartan) on fibrosis and immune inflammation markers in hypertensive patients with chronic kidney disease (CKD) after ischemic stroke (IS).Material and methods. The study included 76 hypertensive patients aged 60-...
Saved in:
| Main Authors: | O. A. Osipova, E. V. Gosteva, O. N. Belousova, T. P. Golivets, J. Yu. Chefranova, Yu. A. Lykov, A. N. Khachaturov, N. I. Golovina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2021-11-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3078 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dynamics of fibrotic and vascular endothelial dysfunction markers in elderly hypertensive patients after ischemic stroke receiving beta-blockers
by: O. A. Osipova, et al.
Published: (2022-01-01) -
Efficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes
by: A. M. Kochergina, et al.
Published: (2023-11-01) -
Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors
by: S. V. Nedogoda, et al.
Published: (2020-08-01) -
Coadministration of Cardiomagnyl with Edarbi/Edarbi Clo in comparison with enteric-coated acetylsalicylic acid and renin-angiotensin-aldosterone system blockers in patients with hypertension and atherosclerotic cardiovascular diseases in the Russian Federation. Results of the CARAT study
by: F. T. Ageev, et al.
Published: (2025-07-01) -
Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)